Replies to post #137916 on Biotech Values

[genisi]

GS-7977/Riba datasets

Q: When are these results due?

A: Results from ongoing studies in genotype 1 treatment-naïve patients will be available in the coming months. The first data evaluating GS-7977 plus RBV for 12 weeks in genotype 1 naïve patients will come from an arm of the QUANTUM study with 25 patients at the end of the first quarter of 2012. This will be followed in the second quarter by data from the ELECTRON study involving 25 patients and, early in the third quarter, data on GS-7977 and RBV treatment for 24 weeks from an arm of the QUANTUM study will become available.

Source: http://www.gilead.com/pr_1662331

[oc631]

When are these results due?

As Idit pointed out sometime near the end of March. One thing to keep in mind is that viral relapse was found four weeks into the follow-up period in nulls so stunning 12-week SVR data doesn't necessarily mean the results will continue to hold during follow-up.

I'm inclined to agree because I think the goal is to ultimately remove riba as well.

From a patient tolerability standpoint this may be true. Ideally GILD would prefer to dominate the space for treatment-naive patients using the generic ribavirin combination.